Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI‐TOF

Surface enhanced laser desorption and ionization‐time‐of‐flight (SELDI‐TOF) is an evolving proteomic technology for improving biomarker discovery that allows for rapid and sensitive analysis of complex protein mixtures generated from body fluids, cells, and/or tissues. SELDI—based profiling identifies unique, differentially expressed proteins relating to specific cancer‐related disease states. We utilized SELDI‐TOF following pre‐processing with molecular separation and chemical fractionation of cell membrane extracts from three Dunning rat prostate cancer cell lines of varying metastatic potential to search novel proteins that are differentially expressed.

[1]  Thomas P Conrads,et al.  The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. , 2002, Biochemical and biophysical research communications.

[2]  E. Petricoin,et al.  Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip , 2000 .

[3]  S. Weinberger,et al.  Recent advancements in surface‐enhanced laser desorption/ionization‐time of flight‐mass spectrometry , 2000, Electrophoresis.

[4]  E. Frenkel,et al.  Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents. , 2002, The Journal of urology.

[5]  J. Oesterling,et al.  Prostate specific antigen: a decade of discovery--what we have learned and where we are going. , 1999, The Journal of urology.

[6]  Jean-Charles Sanchez,et al.  Proteomics: new perspectives, new biomedical opportunities , 2000, The Lancet.

[7]  G I Murray,et al.  Proteomics: a new approach to the study of disease , 2000, The Journal of pathology.

[8]  Jerome P. Richie,et al.  Diagnosis and Staging of Prostate Cancer , 2003 .

[9]  S Hanash,et al.  Proteomics in early detection of cancer. , 2001, Clinical chemistry.

[10]  A. Vlahou,et al.  Proteomic approaches to biomarker discovery in prostate and bladder cancers , 2001, Proteomics.

[11]  D. Bostwick,et al.  Workgroup I: Rodent models of prostate cancer , 1998, The Prostate.

[12]  S M Hanash,et al.  Proteomic Approaches within the NCI Early Detection Research Network for the Discovery and Identification of Cancer Biomarkers , 2001, Annals of the New York Academy of Sciences.

[13]  William B. Isaacs,et al.  Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers , 1986 .

[14]  E. Fung,et al.  Protein biochips for differential profiling. , 2001, Current opinion in biotechnology.

[15]  T. Yip,et al.  New desorption strategies for the mass spectrometric analysis of macromolecules , 1993 .

[16]  J. Isaacs.  The R-3327 system of rat prostatic cancers. , 1996, Urologic oncology.

[17]  Arul M Chinnaiyan,et al.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. , 2003, Journal of the National Cancer Institute.

[18]  P. Bunting,et al.  A guide to the interpretation of serum prostate specific antigen levels. , 1995, Clinical biochemistry.

[19]  G. Wright,et al.  Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures , 1999, Prostate Cancer and Prostatic Diseases.

[20]  G. Wright,et al.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. , 2001, The American journal of pathology.

[21]  M. Bosland.  Use of Animal Models in Defining Efficacy of Chemoprevention Agents against Prostate Cancer , 1999, European Urology.

[22]  Peter H Gann,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.

[23]  N. Anderson,et al.  Proteomics: applications in basic and applied biology. , 2000, Current opinion in biotechnology.

[24]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[25]  K. Meehan,et al.  Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer , 2002, The Prostate.

[26]  M. Terris,et al.  Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. , 2003, Urology.

[27]  D. S. Coffey,et al.  Cell surface charge in predicting metastatic potential of aspirated cells from the Dunning rat prostatic adenocarcinoma model. , 1988, The Journal of urology.

[28]  Ian M Thompson,et al.  Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker , 2004, Cancer.

[29]  D. Hochstrasser,et al.  Introduction to the Proteome , 1997 .

[30]  E. Petricoin,et al.  New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. , 2001, Urology.

[31]  A. Diokno,et al.  Clean, intermittent self-catheterization in the treatment of urinary tract disease. , 1972, The Journal of urology.

[32]  M. Hendrix,et al.  A novel immunological model for the study of prostate cancer. , 1999, Cancer research.